Cebranopadol: Phase III data

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary endpoint of non-inferiority to twice-daily oral

Read the full 356 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE